Comparative Pharmacology
Head-to-head clinical analysis: NILOTINIB versus QLOSI.
Peer-Reviewed Evidence
Head-to-head clinical analysis: NILOTINIB versus QLOSI.
NILOTINIB vs QLOSI
Comparing the clinical profiles, pharmacokinetic behaviors, and safety indices of these two therapeutic agents.
Tyrosine kinase inhibitor targeting BCR-ABL, c-KIT, and PDGFR. Binds to inactive conformation of ABL kinase, preventing ATP binding and substrate phosphorylation.
QLOSI is a monoclonal antibody that binds to and inhibits the activity of interleukin-5 (IL-5), thereby reducing eosinophil production and survival.
300 mg orally twice daily for newly diagnosed chronic phase CML; 400 mg orally twice daily for resistant or intolerant CML. Take on an empty stomach (no food for 2 hours before and 1 hour after).
100 mg orally once daily.
None Documented
None Documented
Terminal elimination half-life approximately 17 hours (range 14-20 hours), supporting twice-daily dosing.
Clinical Note
moderateNilotinib + Digoxin
"Nilotinib may decrease the cardiotoxic activities of Digoxin."
Clinical Note
moderateNilotinib + Digitoxin
"Nilotinib may decrease the cardiotoxic activities of Digitoxin."
Clinical Note
moderateNilotinib + Deslanoside
"Nilotinib may decrease the cardiotoxic activities of Deslanoside."
Clinical Note
moderateNilotinib + Acetyldigitoxin
"Nilotinib may decrease the cardiotoxic activities of Acetyldigitoxin."
Terminal elimination half-life is approximately 9 hours; clinical context: allows twice-daily dosing in patients with normal renal function.
Primarily fecal (93% of absorbed dose) via biliary excretion; renal excretion accounts for <1% of unchanged drug.
Primarily renal excretion of unchanged drug (approximately 85%), with the remainder eliminated via biliary/fecal routes (15%).
Category D/X
Category C
Kinase Inhibitor
Kinase Inhibitor